Bhaveshkumar A. Patel
Bhaveshkumar A. Patel has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Akhilesh Kumar Kuril
Department of Pharmacy, Bhagwant University
1 shared publication- Anasuya Patil
Department of Pharmaceutics, KLE College of Pharmacy
1 shared publication Ankur Vashi
Flamma USA Group, Flamma USA
1 shared publication- Ankur Vashi
Analytical Department, Flamma USA, Phoenixville Pike-Malvern, PA 19355, Malvern, United States
1 shared publication - Dhruv Dev
Department of Pharmacy, Shivalik College of Pharmacy Nangal
1 shared publication - Gaurav Tiwari
PSIT-Pranveer Singh Institute of Technology (Pharmacy), Kalpi Road, Bhauti, Kanpur-208020, India
1 shared publication
Latest Publications
- 16 September 2026
- Published by SAGE Publications in Journal of Generic Medicines
AI-driven insights for regulatory decision-making in drug-device combinations
Medical devices or drug-device combination products are achieving acceptance for their use in early diagnosis, examination and the treatment delivery of various diseases. Artificial intelligence is reforming the healthcare domain by providing tremendous opportunities through increased precision detection, patient - specific treatment plan and improved clinical outcomes. Although these innovations provide potential advantages, their limitations in digital safety, data protection, and data authenticity in real-world cannot be overlooked along with other ethical challenges. Recent regulatory guidelines and good AI practice are designed to mitigate these challenges by continuous monitoring of AI models and constant improvement in them. Lastly, regulatory agency is expected to expedite research on AI accompanied devices for better clinical precision and improved tailored treatments.
- 16 September 2026
- Published by SAGE Publications in Journal of Generic Medicines
AI-driven insights for regulatory decision-making in drug-device combinations
Medical devices or drug-device combination products are achieving acceptance for their use in early diagnosis, examination and the treatment delivery of various diseases. Artificial intelligence is reforming the healthcare domain by providing tremendous opportunities through increased precision detection, patient - specific treatment plan and improved clinical outcomes. Although these innovations provide potential advantages, their limitations in digital safety, data protection, and data authenticity in real-world cannot be overlooked along with other ethical challenges. Recent regulatory guidelines and good AI practice are designed to mitigate these challenges by continuous monitoring of AI models and constant improvement in them. Lastly, regulatory agency is expected to expedite research on AI accompanied devices for better clinical precision and improved tailored treatments.
- 1 February 2026
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Biotechnology
- Vol. 27 (3) , 290-309
Niosomal Encapsulation of Anti-cancer Peptides: A Revolutionary Strategy in Cancer Therapy
Cancer treatment has evolved significantly over the years, incorporating a range of modalities including surgery, radiation, chemotherapy, and immunotherapy. However, challenges such as drug resistance, systemic toxicity, and poor targeting necessitate innovative approaches. Peptides have gained attention in cancer therapy due to their specificity, potency, and ability to modulate various biological pathways. Peptide-based drugs can act as hormones, enzyme inhibitors, or targeting ligands, contributing to their versatile role in cancer treatment. However, peptides face several challenges, including instability, rapid degradation, and poor bioavailability. One promising strategy is the use of niosomal delivery systems for peptidebased therapies. Niosomes, which resemble liposomes in structure, are vesicles based on nonionic surfactants. They are composed of a bilayer created through the self-assembly of non-ionic surfactants in water, enabling them to encapsulate hydrophilic, lipophilic, and amphiphilic drugs. Their unique properties, such as biocompatibility, biodegradability, and ability to encapsulate diverse therapeutic agents, make them suitable for drug delivery applications. This review aims to explore how the niosomal preparation of peptides can revolutionize oncology drugs by overcoming critical challenges like drug resistance, systemic toxicity, poor targeting, instability, rapid degradation, and low bioavailability. This review aims to explore how niosomes can specifically address key limitations in cancer therapy, including targeting, bioavailability, and stability of peptide-based drugs. By consolidating recent advancements, the review sheds light on how niosomal encapsulation can overcome barriers in cancer treatment and improve therapeutic outcomes for patients.
- 1 February 2026
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Biotechnology
- Vol. 27 (3) , 290-309
Niosomal Encapsulation of Anti-cancer Peptides: A Revolutionary Strategy in Cancer Therapy
Cancer treatment has evolved significantly over the years, incorporating a range of modalities including surgery, radiation, chemotherapy, and immunotherapy. However, challenges such as drug resistance, systemic toxicity, and poor targeting necessitate innovative approaches. Peptides have gained attention in cancer therapy due to their specificity, potency, and ability to modulate various biological pathways. Peptide-based drugs can act as hormones, enzyme inhibitors, or targeting ligands, contributing to their versatile role in cancer treatment. However, peptides face several challenges, including instability, rapid degradation, and poor bioavailability. One promising strategy is the use of niosomal delivery systems for peptidebased therapies. Niosomes, which resemble liposomes in structure, are vesicles based on nonionic surfactants. They are composed of a bilayer created through the self-assembly of non-ionic surfactants in water, enabling them to encapsulate hydrophilic, lipophilic, and amphiphilic drugs. Their unique properties, such as biocompatibility, biodegradability, and ability to encapsulate diverse therapeutic agents, make them suitable for drug delivery applications. This review aims to explore how the niosomal preparation of peptides can revolutionize oncology drugs by overcoming critical challenges like drug resistance, systemic toxicity, poor targeting, instability, rapid degradation, and low bioavailability. This review aims to explore how niosomes can specifically address key limitations in cancer therapy, including targeting, bioavailability, and stability of peptide-based drugs. By consolidating recent advancements, the review sheds light on how niosomal encapsulation can overcome barriers in cancer treatment and improve therapeutic outcomes for patients.
- 10 August 2025
- Published by Taylor & Francis in Journal of Biomaterials Science, Polymer Edition
- Vol. 37 (6) , 1193-1225
Overcoming resistance: targeted nanomedicine solutions for cancer therapy
Multidrug resistance (MDR), or tumor drug resistance, is still one of the most serious issues in the treatment of cancer, which directly affects the efficacy of cancer therapies and the survival of patients. This review focuses on describing how nanotechnology in medicine may help to address MDR and presents novel approaches that may revolutionize targeted cancer treatment. In this review, we discuss the potential of different types of nanoparticles, such as liposomes, polymeric nanoparticles and metallic nanoparticles for targeted delivery, and the use of these nanoparticles to kill tumor cells without damaging the normal cells. Further, we discuss emerging approaches, including RNA interference, CRISPR-Cas9 gene editing, and stimuli-responsive nanoparticles, all of which indicate future directions for MDR combat. Based on such developments, nanomedicine turns out to be a crucial handle in oncology, end-user for superior and refine style of managing cancer. This review establishes the imperative practicing of transdisciplinary integration in order to attain the optimum advancement of nanomedicine in combating MDR and enhancing the survival prognosis of different forms of cancer in patients all over the world.
- 10 August 2025
- Published by Taylor & Francis in Journal of Biomaterials Science, Polymer Edition
- Vol. 37 (6) , 1193-1225
Overcoming resistance: targeted nanomedicine solutions for cancer therapy
Multidrug resistance (MDR), or tumor drug resistance, is still one of the most serious issues in the treatment of cancer, which directly affects the efficacy of cancer therapies and the survival of patients. This review focuses on describing how nanotechnology in medicine may help to address MDR and presents novel approaches that may revolutionize targeted cancer treatment. In this review, we discuss the potential of different types of nanoparticles, such as liposomes, polymeric nanoparticles and metallic nanoparticles for targeted delivery, and the use of these nanoparticles to kill tumor cells without damaging the normal cells. Further, we discuss emerging approaches, including RNA interference, CRISPR-Cas9 gene editing, and stimuli-responsive nanoparticles, all of which indicate future directions for MDR combat. Based on such developments, nanomedicine turns out to be a crucial handle in oncology, end-user for superior and refine style of managing cancer. This review establishes the imperative practicing of transdisciplinary integration in order to attain the optimum advancement of nanomedicine in combating MDR and enhancing the survival prognosis of different forms of cancer in patients all over the world.
- 10 November 2024
- Published by Taylor & Francis in Journal of Biomaterials Science, Polymer Edition
- Vol. 36 (6) , 711-742
Preparation, optimization, and evaluation of ligand-tethered atovaquone-proguanil-loaded nanoparticles for malaria treatment
- 10 November 2024
- Published by Taylor & Francis in Journal of Biomaterials Science, Polymer Edition
- Vol. 36 (6) , 711-742
Preparation, optimization, and evaluation of ligand-tethered atovaquone-proguanil-loaded nanoparticles for malaria treatment